Potential negative impact of reputed regulators decisions on the approval status of new cancer drugs in Latin American countries: A descriptive analysis

Article

Abstract: Background Many new cancer drugs are being approved by reputed regulatory authorities without eviden

Palabras claves:

Autores:

Cañás M., Carlos E. Durán, Christiaens T., Elseviers M., Stichele R.V., Urtasun M.A.

Fuentes:

scopus